Avalo Therapeutics, Inc.AVTXNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank85
3Y CAGR+12.9%
5Y CAGR+6.9%
Year-over-Year Change
Research and development spending
3Y CAGR
+12.9%/yr
vs +52.5%/yr prior
5Y CAGR
+6.9%/yr
Recent acceleration
Acceleration
-39.7pp
Decelerating
Percentile
P85
Within normal range
vs 5Y Ago
1.4x
Solid growth
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $45.00M | -13.6% |
| 2024 | $52.08M | +277.8% |
| 2023 | $13.78M | -56.0% |
| 2022 | $31.31M | -47.7% |
| 2021 | $59.84M | +85.9% |
| 2020 | $32.19M | +173.7% |
| 2019 | $11.76M | +103.3% |
| 2018 | $5.79M | +32.3% |
| 2017 | $4.37M | -56.9% |
| 2016 | $10.15M | - |